BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19817678)

  • 1. Denileukin diftitox: a novel immunotoxin.
    Manoukian G; Hagemeister F
    Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
    Wong BY; Gregory SA; Dang NH
    Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with denileukin diftitox (ONTAK).
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.
    Wong BY; Ma Y; Fitzwilson R; Dang NH
    Am J Hematol; 2008 Jul; 83(7):596-8. PubMed ID: 18383317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies for chronic lymphocytic leukemia.
    Mavromatis BH; Cheson BD
    Blood Rev; 2004 Jun; 18(2):137-48. PubMed ID: 15010151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
    Kuzel TM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
    McCann S; Akilov OE; Geskin L
    Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
    Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
    Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
    Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma.
    Di Venuti G; Nawgiri R; Foss F
    Clin Lymphoma; 2003 Dec; 4(3):176-8. PubMed ID: 14715100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.